This study reports clinical efficacy results of 10 patients diagnosed withprogressive, metastatic BRAF V600E-mutated RAI-refractory thyroid cancer treatedwith either dabrafenib (a BRAF inhibitor) alone or a combination of dabrafenib andtrametinib (BRAF and MEK inhibitors) as first-, secondor third-line therapy. This evidence concerns the gene MAP2K7 and thyroid cancer.